Skip to main content

Patritumab Deruxtecan Yields Meaningful, Enduring Activity in EGFR+ NSCLC

*January 2024*

Treatment with patritumab deruxtecan (HER3-DXd) in patients with locally advanced or metastatic, EGFR-mutated non–small cell lung cancer (NSCLC) resulted in clinically meaningful efficacy and long-lasting responses in those who progressed following EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy, according to data from the phase 2 HERTHENA-Lung01 study (NCT04619004).

In a population of 225 patients who were treated with HER3-DXd at a dose of 5.6 mg/kg once every 3 weeks, the confirmed overall response rate (ORR) by blinded independent central review (BICR) was 29.8% (95% CI, 23.9%-36.2%). Investigators reported a median duration of response (DOR) of 6.4 months (95% CI, 4.9-7.8), and 43.3% had responses lasting 6 months or longer.

“For patients with advanced EGFR-mutated NSCLC that has progressed after EGFR TKI therapy and [platinum-based chemotherapy], current treatment options provide only limited clinical benefit,” the authors wrote. “To our knowledge, the results of HERTHENA-Lung01 presented here provide the largest evaluation to date of the efficacy and safety of HER3-DXd [monotherapy] once every 3 weeks in this population, and also provide the largest assessment of a targeted therapy after the failure of osimertinib [Tagrisso].” Read more.